Department of Medicine and Molecular Physiology and Biophysics, University of Vermont Larner College of Medicine, Burlington, Vermont.
Institute of Experimental and Clinical Pharmacology und Toxicology, Faculty of Medicine, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
Am J Physiol Heart Circ Physiol. 2021 Jun 1;320(6):H2188-H2200. doi: 10.1152/ajpheart.00858.2020. Epub 2021 Apr 16.
The interaction of phospholamban (PLB) and the sarcoplasmic reticulum Ca-ATPase (SERCA2a) is a key regulator of cardiac contractility and a therapeutic target in heart failure (HF). PLB-mediated increases in SERCA2a activity improve cardiac function and HF. Clinically, this mechanism can only be exploited by a general activation of the proteinkinase A (PKA), which is associated with side effects and adverse clinical outcomes. A selective interference of the PLB-SERCA2a interaction is desirable but will require novel tools that allow for an integrated assessment of this interaction under both physiological and pathophysiological conditions. A circularly permutated green fluorescent protein (cpGFP) was interposed between SERCA2a and PLB to result into a single SERCA2a-cpGFP-PLB recombinant protein (SGP). Expression, phosphorylation, fluorescence, and function of SGP were evaluated. Expression of SGP-cDNA results in a functional recombinant protein at the predicted molecular weight. The PLB domain of SGP retains its ability to polymerize and can be phosphorylated by PKA activation. This increases the fluorescent yield of SGP by between 10% and 165% depending on cell line and conditions. In conclusion, a single recombinant fusion protein that combines SERCA2a, a circularly permutated green fluorescent protein, and PLB can be expressed in cells and can be phosphorylated at the PLB domain that markedly increases the fluorescence yield. SGP is a novel cellular SERCA2a-PLB interaction monitor. This study describes the design and characterization of a novel biosensor that can visualize the interaction of SERCA2a and phospholamban (PLB). The biosensor combines SERCA2a, a circularly permutated green fluorescent protein, and PLB into one recombinant protein (SGP). Proteinkinase A activation results in phosphorylation of the PLB domain and is associated with a marked increase in the fluorescence yield to allow for real-time monitoring of the SERCA2a and PLB interaction in cells.
肌浆网钙 ATP 酶(SERCA2a)与磷酸化酶调节蛋白(PLB)的相互作用是心脏收缩力的关键调节因子,也是心力衰竭(HF)的治疗靶点。PLB 介导的 SERCA2a 活性增加可改善心脏功能和 HF。临床上,这种机制只能通过普遍激活蛋白激酶 A(PKA)来利用,而这与副作用和不良临床结局有关。选择性干扰 PLB-SERCA2a 相互作用是可取的,但需要新的工具,以便在生理和病理生理条件下对这种相互作用进行综合评估。一种环状排列的绿色荧光蛋白(cpGFP)被插入 SERCA2a 和 PLB 之间,形成单个 SERCA2a-cpGFP-PLB 重组蛋白(SGP)。评估了 SGP 的表达、磷酸化、荧光和功能。SGP-cDNA 的表达导致预测分子量的功能性重组蛋白。SGP 的 PLB 结构域保留其聚合能力,并可被 PKA 激活磷酸化。这会根据细胞系和条件的不同,使 SGP 的荧光产率增加 10%至 165%。总之,可在细胞中表达一种将 SERCA2a、环状排列的绿色荧光蛋白和 PLB 结合在一起的单个重组融合蛋白,并且可以在 PLB 结构域磷酸化,这明显增加了荧光产率。SGP 是一种新型的细胞 SERCA2a-PLB 相互作用监测器。本研究描述了一种新型生物传感器的设计和特性,该传感器可可视化 SERCA2a 和磷酸化酶调节蛋白(PLB)的相互作用。该生物传感器将 SERCA2a、环状排列的绿色荧光蛋白和 PLB 结合在一起形成一个重组蛋白(SGP)。蛋白激酶 A 激活导致 PLB 结构域磷酸化,与荧光产率的显著增加相关,允许在细胞中实时监测 SERCA2a 和 PLB 相互作用。